Patent Settlements Stir Supreme Court Interest During Slow Term For Pharma Cases
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
High court seeks Solicitor General's view on whether patent settlements blocking authorized generics are anticompetitive; court denies GSK petition challenging payer claims in Avandia litigation.
You may also be interested in...
Do Payers Pay More If Drug Risks Are Not Disclosed? GSK Seeks Supreme Court Answer
GlaxoSmithKline petitions court to review third party payers' RICO claims in Avandia litigation; PhRMA cites 'growing torrent' of such suits against drug makers.
PhRMA Fears 'Potentially Limitless' State Suits After Risperdal Case
US Supreme Court denies J&J petition seeking review of South Carolina’s $124m judgment related to Risperdal marketing, giving state unfair trade practice laws a boost.
J&J Petitions Supreme Court On Pre-emption, ‘Clear Evidence’ In OTC Litigation
Johnson & Johnson files a writ of certiorari asking the Supreme Court to review a $140m judgment against the firm in Massachusetts. Questions over “clear evidence” needed for FDA decision to pre-empt state courts are at heart of issue and need the court’s consideration.